These policies apply to drugs billed under the medical benefit.

Acthar Gel Medical Policy

Acute Hepatic Porphyria (AHP) Medical Policy

Adstiladrin Medical Policy

Alpha 1-Proteinase Inhibitors Medical Policy

Antipsychotics, Long-Acting Injectables Medical Policy

Bevacizumabs Medical Policy

Botulinum Toxins Medical Policy

Casgevy Medical Policy

Colony Stimulating Factors Medical Policy

Denosumabs Medical Policy

Elevidys Medical Policy

Erythropoesis Stimulating Agents (ESA) Medical Policy

Fabry Disease Medical Policy

Gaucher's Disease Type 1 Medical Policy

Gonadotropin Releasing Hormones (GnRH) Analogs Medical Policy

hATTR Medical Policy

Hemgenix Medical Policy

Hemophilia Medical Policy

Hyaluronic Acid Derivatives (HAD) Medical Policy

Immune Globulins Medical Policy

Inflammatory Conditions Medical Policy

Infliximabs Medical Policy

IUDs Medical Policy

IV Iron Medical Policy

Lenmeldy Medical Policy

Lyfgenia Medical Policy

Mental Health Medical Policy

Multiple Sclerosis Medical Policy

Myasthenia Gravis Medical Policy

Nasopharyngeal Carcinoma (NPC) Medical Policy

Phesgo Medical Policy

Primary Hyperoxalruia Type 1 (PH1) Medical Policy

Prostacyclin Analogs Medical Policy

Rituximabs Medical Policy

Roctavian Medical Policy

Somatostatin Analogs Medical Policy

Specialty Asthma Medical Policy

Spinal Muscular Atrophy Medical Policy

Substance Use Disorder Medical Policy

Traztuzumabs Medical Policy

VEGF Inhibitors Medical Policy

Vyjuvek Medical Policy

Ycanth Medical Policy

Zevaskyn Medical Policy

Zynteglo Medical Policy